HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $56 price target.
Share
Why It Matters
A stock expert says Mineralys is still worth buying. They think the stock could reach $56 per share.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.